
Pet medicine and vaccine maker Dechra put out a second profit warning in three months today, putting a potential buyout at risk, after a number of US wholesalers cut back on stocking its products.
The firm, which acquired Ivermectin maker Med-Pharmex last year, warned that “widely reported destocking” in the US was hitting its profits in February, but now said that this has been lasting longer than previously expected.